Tag: NASDAQ: JAN

Business

Janone Inc (NASDAQ: JAN) Selects Monitoring Collaborator for Phase 2b Pilot as Trial Strategy is Organized for FDA Filing

Janone Inc (NASDAQ: JAN) today proclaimed its choice of Avania as its monitoring collaborator in the imminent premeditated Phase 2b pilot of principal product applicant JAN101 for handling Peripheral Artery Disease (PAD). Avania will accomplish all monitoring processes related to pilot readiness and implementation, counting safeguarding acquiescence with the FDA’s […]